Evidence map›Paper›PMID 36742414›Full record

ArticleFrontiers in endocrinology2023

Augmentation of IFN-γ by bone marrow derived immune cells in the presence of severe suppression of IFN-γ in gingivae induced by zoledronic acid and denosumab in Hu-BLT mice model of ONJ.

Kawaljit Kaur, Yujie Sun, Keiichi Kanayama, Kenzo Morinaga, Akishige Hokugo, Ichiro Nishimura, Anahid Jewett

Open access · goldAbstract read
In one paragraph

Article in Frontiers in endocrinology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Immune Dysfunction in Medication-Related Osteonecrosis of the Jaw.International journal of molecular sciences · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Kawaljit KaurWeintraub Center for Reconstructive Biotechnology, UCLA School of Dentistry, Los Angeles, CA, United States.
Yujie SunWeintraub Center for Reconstructive Biotechnology, UCLA School of Dentistry, Los Angeles, CA, United States.
Keiichi KanayamaWeintraub Center for Reconstructive Biotechnology, UCLA School of Dentistry, Los Angeles, CA, United States.
Kenzo MorinagaWeintraub Center for Reconstructive Biotechnology, UCLA School of Dentistry, Los Angeles, CA, United States.
Akishige HokugoWeintraub Center for Reconstructive Biotechnology, UCLA School of Dentistry, Los Angeles, CA, United States.
Ichiro NishimuraWeintraub Center for Reconstructive Biotechnology, UCLA School of Dentistry, Los Angeles, CA, United States.
Anahid JewettWeintraub Center for Reconstructive Biotechnology, UCLA School of Dentistry, Los Angeles, CA, United States.
University of California, Los Angeles · USFukuoka Dental College · JP

Funding

UCLA-CDU CFARP30AI152501 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SCOTT G KITCHEN · 2022 to 2026
$15.6M
NIAID NIH HHS P30 AI152501
6 · The paper itself

Abstract

Introduction: The potential mechanisms governing drug induced osteonecrosis of the jaw (ONJ) is not well understood, and is one of the objectives of this study. Thus, we tested the release of IFN-γ within different immune compartments including bone marrow and gingivae upon treatment with zoledronic acid (ZOL) and denosumab which are known to induce ONJ in susceptible individuals. Methods: We used humanized-BLT mouse model for the Results: Percentages of B cells are much higher in wild-type mice whereas the proportions of immune subsets in humans and reconstituted hu-BLT peripheral-blood are similar. Therefore, hu-BLT mice are preferable model to study human disease, in particular, immune-pathologies induced by ZOL and denosumab. Both agents resulted in a severe suppression of IFN-γ in the gingiva, whereas they heightened the release of IFN-γ and NK cell-mediated cytotoxicity by the BM-derived immune cells. ZOL increased the IFN-γ secretion by the spleen and peripheral blood immune cells, whereas denosumab decreased the release IFN-γ by these cells significantly. Discussion: ZOL and denosumab may likely suppress IFN-γ secretion in gingiva through different mechanisms. In addition, to the suppression of IFN-γ secretion, denosumab mediated effect could in part be due to the decrease in the bone resorptive function of osteoclasts due to the induction of antibody dependent cellular cytotoxicity and lysis of osteoclasts, whereas ZOL is able to mediate cell death of osteoclasts directly. Suppression of IFN-gamma in gingiva is largely responsible for the inhibition of immune cell function, leading to dysregulated osteoblastic and osteoclastic activities. Restoration of IFN-gamma in the local microenvironment may result in establishment of homeostatic balance in the gingiva and prevention of osteonecrosis of jaw.

Indexed as

DenosumabInterferon-gammaOsteonecrosisZoledronic AcidAnimalsBone MarrowDiphosphonatesGingivaHumansMiceDenosumabDiphosphonatesInterferon-gammaZoledronic Acidantibody-dependent cellular cytotoxicity (ADCC)cytotoxicitydenosumabhumanized-BLT miceIFN-γNK cellsosteonecrosis of the jawzoledronic acid

Identifiers

PMID36742414
PMCPMC9895394
OpenAlexW4317630050

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.